<DOC>
	<DOCNO>NCT01617967</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , pharmacokinetics pharmacodynamics multiple dos ALN-TTR02 patient transthyretin ( TTR ) mediate amyloidosis ( ATTR ) .</brief_summary>
	<brief_title>Trial Evaluate Safety Tolerability ALN-TTR02 Transthyretin ( TTR ) Amyloidosis</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Body mass index must 17 kg/m2 â‰¤ 33 kg/m2 ; Women childbearing potential must negative pregnancy test , breast feeding , must use appropriate contraception ; Males agree use appropriate contraception ; Diagnosis TTR amyloidosis ; Adequate blood count , liver renal function ; Willing give write informed consent willing comply study requirement . Known human immunodeficiency virus ( HIV ) positive status know suspected systemic bacterial , viral , parasitic , fungal infection ; Received investigational agent , tafamidis diflunisal , within 30 day prior first dose study drug administration ; Prior liver transplant ; Poor cardiac function ; Considered unfit study Principal Investigator ; Employee family member sponsor clinical study site personnel .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>RNAi therapeutic</keyword>
</DOC>